Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regen Biopharma ( (RGBP) ) just unveiled an announcement.
On August 5, 2025, Regen Biopharma, Inc. entered into a securities purchase agreement with Labrys Fund II LP, resulting in the issuance of a 6% convertible promissory note valued at $100,000. This agreement allows Labrys the option to convert the note into common stock, potentially impacting the company’s stock trading dynamics and financial strategy.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing innovative treatments and therapies. The company is involved in the research and development of products aimed at addressing critical medical needs.
Average Trading Volume: 74,769
Technical Sentiment Signal: Sell
Current Market Cap: $1.63M
For a thorough assessment of RGBP stock, go to TipRanks’ Stock Analysis page.